IMPLANET to Attend the 13th Annual Meeting of the German Society for Spine Surgery (DWG)
December 04 2018 - 2:00AM
Business Wire
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0010458729, eligible
for PEA-PME equity savings plans; OTCQX: IMPZY) (Paris:ALIMP)
(OTCQX:IMPZY), a medical technology company specializing in
vertebral and knee-surgery implants, is announcing that it will
attend the 13th Annual Meeting of the German Society for Spine
Surgery (DWG), which will take place December 6-8 in
Wiesbaden, Germany.
Implanet’s presence at booth no. 62 will give its team the
opportunity to present to German surgeons Jazz® Evo and Jazz® Cap,
the latest implants developed to meet the constraints associated
with vertebral fusion indications in adults. The German market,
Europe’s largest and worth ~$300 million, is addressed by
Implanet GmbH.
The DWG is a German medical society whose members specialize in
vertebral column surgery. The DWG, which was founded in 2006, aims
to promote an ethical and data-backed therapeutic approach for the
treatment of vertebral column disorders. Its goal is to formulate
policies and implement initiatives to deepen knowledge, undertake
research and promote spine health specialties. DWG’s membership of
over 1,600 health professionals is made up of orthopedic and neuro
surgeons, trauma specialists, researchers and other related
clinicians.
“The establishment of our Implanet GmbH subsidiary in Frankfurt,
Germany, has brought us another step forward in the process of
replicating our tried and tested direct sales model in the European
market. We are delighted to be able to showcase Jazz® Evo and Jazz®
Cap at DWG’s 13th Annual Meeting in Germany, Europe’s largest
market for degenerative spine conditions”, said CEO Ludovic
Lastennet.
About IMPLANETFounded in 2007, IMPLANET is a medical
technology company that manufactures high-quality implants for
orthopedic surgery. Its flagship product, the JAZZ®
latest-generation implant, aims to treat spinal pathologies
requiring vertebral fusion surgery. Protected by four families of
international patents, JAZZ® has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United
States and the CE mark. IMPLANET employs 46 staff and recorded 2017
sales of €7.8 million. For further information, please visit
www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US
subsidiary in Boston in 2013.
IMPLANET is listed on Euronext™ Growth market in Paris. The
Company would like to remind that the table for monitoring the
BEOCABSA, OCA, BSA and the number of shares outstanding, is
available on its website:
http://www.implanet-invest.com/suivi-des-actions-80
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181203005667/en/
IMPLANETLudovic LastennetCEOTel. : +33 (0)5 57 99 55
55investors@implanet.com
NewCapInvestor RelationsJulie CoulotTel. : +33 (0)1 44 71
20 40implanet@newcap.eu
NewCapMedia RelationsNicolas MerigeauTel. : +33 (0)1 44
71 94 98implanet@newcap.eu
AlphaBronzeUS-Investor RelationsPascal NigenTel.: +1 917
385 21 60implanet@alphabronze.net
Implanet (EU:ALIMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Implanet (EU:ALIMP)
Historical Stock Chart
From Apr 2023 to Apr 2024
